A 24 months, prospective, randomized, double-blind study to assess the effect of daily oral administration of 2 g of strontium ranelate versus placebo on bone mineral density in postmenopausal osteoporotic women previously treated with oral bisphosphonates.

Trial Profile

A 24 months, prospective, randomized, double-blind study to assess the effect of daily oral administration of 2 g of strontium ranelate versus placebo on bone mineral density in postmenopausal osteoporotic women previously treated with oral bisphosphonates.

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Aug 2015

At a glance

  • Drugs Strontium ranelate (Primary)
  • Indications Fracture; Postmenopausal osteoporosis
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 15 Aug 2015 Status changed from recruiting to completed, as reported by European Clinical Trials Database record.
    • 28 Dec 2012 Planned End Date changed from 30 Aug 2014 to 30 Aug 2015 as reported by European Clinical Trials Database.
    • 11 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top